ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Every earnings call announcement on NSE and BSE that our alert engine sent, newest first. Each one has its own page with the summary, the key figures and the original filing.
Time
9,412 announcements
UTI AMC reports steady Q2 FY27 growth despite market volatility, focusing on its Mission 2031 strategy for AUM expansion.
UltraTech Q2 FY27 (transcript filed under India Cements cover letter): volume +13.8%, profit +21% YoY; spot prices ~5% above Q2 average; H2 cost pressure persists.
Q2 FY27 revenue INR 982 Mn, down 6% YoY, up 3% QoQ. EBITDA INR 27 Mn; PAT loss INR 22 Mn. AI revenue 12.4% of total.
Q2 FY27 standalone revenue ₹3,595 Cr (+26% YoY), EBITDA ₹500 Cr (+14%), margin 14.2% (down 1.7ppt YoY). PAT ₹190 Cr (+8%). Grey volume up 21%.
Record Q2 revenue of ₹2,529 Cr (+145% YoY) with 27% operational EBITDA margin; FY29 margin target lifted to 30%. Reported EBITDA and PAT include a one-time ₹161 Cr tariff refund.
Sunteck Realty maintains strong growth momentum with a 25% CAGR across major operational parameters over five years.
Indoco Remedies hit record quarterly revenue exceeding ₹500 Cr, but faced margin compression from elevated geopolitical freight and material costs.
Veerhealth is aggressively scaling through contract manufacturing for top FMCG players. The 3x revenue target for FY27 hinges on successful capacity expansion and international hotel supply orders.
Lumax reports record revenue surpassing ₹1,500 Cr milestone, driven by robust automotive sector recovery.
Sumitomo Chemical delivered stable H1 performance despite India's fourth weakest monsoon since 2001. Management maintained 20%+ EBITDA margins through cost control and a 22% value growth in specialty products, offsetting volume declines in generic segments.
Sakar Healthcare delivered exceptional growth as its oncology segment scales, with EBITDA doubling and margins expanding significantly due to product-mix shifts. Management is pivoting from a non-oncology focus to high-margin oncology formulations and APIs.
Q2 FY27 consolidated revenue ₹429 Cr (+10% YoY), EBITDA ₹159 Cr (37% margin), PAT ₹91 Cr (+10%). Standalone PAT ₹106 Cr (+27%).
Q2 FY27: net sales ₹50,616 Cr (+26.1% YoY), PAT ₹2,415 Cr (-26.9%). Volume up 26.5%, but EBITDA margin compressed to 9.4% from 12.7%.
Q2 FY27 revenue ₹12,979 lakh (+10% YoY), EBITDA ₹466 lakh, PAT ~₹190 lakh after Q1 loss. Turnaround narrative; no explicit guidance.
Brigade Hotel Ventures delivered strong Q2 growth driven by rate-led performance in Bangalore and Gifts City. EBITDA margins expanded to 37% despite GST headwinds.
Revenue grew 31% YoY, but margins faced pressure from product mix and raw material volatility. Management remains focused on a long-term 20% CAGR despite near-term export headwinds.
Q2 FY27 revenue Rs 321 cr (+27%) and PAT Rs 57 cr (+17%); H1 pre-sales Rs 1,611 cr (+19%). Strategy: capital-light, cash-flow-funded growth; GDV Rs 46,880 cr; leverage 0.09x.
Q2 FY27 revenue ₹1,394 Cr (+24% YoY), EBITDA ₹221 Cr (+51%, 16% margin), PAT ₹111 Cr (+61%). Pinnacle strategy continues; 40% ZettaOne stake (₹189.2 Cr) enters EDMS.
H1 FY27 sales Rs 624 Cr (down 4% YoY), EBITDA Rs 103 Cr at 16.2% margin, PAT Rs 74 Cr (up 4%). Order board Rs 2,040 Cr, up 10% since April; Kobe Steel MoU for non-general compressors.
Q2 FY27 consolidated revenue ₹532.5 Cr (+20.9%) and PAT ₹28.2 Cr (+34.4%). H1 FY27 revenue ₹1,047.5 Cr (+21.1%) and PAT ₹65.0 Cr (+27.6%). NBFC and insurance drive growth.
Q2 FY27 revenue Rs755 Cr (+81%), PAT Rs89 Cr (+117%), EBITDA margin 17.45% (+897bps). H1 revenue Rs1,330 Cr (+57%). CDMO scale-up drives mix.
Q2 FY27 revenue from operations ₹44.58 Cr (+30.0% YoY), PBT ₹5.33 Cr (+9.6%), gross turnover ₹2,914 Cr (+41.2%). Perpetual AD-II licence received 30 July 2026.
Q2 FY27 revenue ₹184 Cr (Q1 ₹179 Cr); Q2 PAT ₹16 Cr vs Q1 ₹24 Cr. H1 revenue ₹363 Cr vs ₹380 Cr; H1 PAT ~₹40 Cr, flat. Feed-cost inflation compressed EBITDA.
Q2FY27 consolidated revenue INR 7,404 Cr (-2.4% YoY), EBITDA INR 1,388 Cr (18.7% margin), PAT INR 878 Cr (11.9%). Record quarterly India revenue; licensing deals in oncology biosimilars and ADCs.
Nazara reported record Q2 revenue driven by the strategic consolidation of BlueTriton and Bestplay. Management is pivoting toward an AI-led 'Global Gaming Platform' model to drive efficiency.
Q2FY27 revenue Rs 62.2 Cr (+40.2% YoY), PAT Rs 5.1 Cr (+23.3%), EBITDA margin 15.2%. Strategy centres on Vision 2030: D2C, EBO roll-out and capacity expansion.
Q2 FY27 revenue ₹4,369 Mn (+42.7% YoY), EBITDA ₹1,760 Mn (+84.6%, 40.3% margin), PAT ₹1,231 Mn (+71.4%). FY27 revenue guidance raised; South Korea semiconductor-chemicals facility inaugurated.
Q2 revenue +42% to ₹188 Cr and PAT +75% to ₹16 Cr, but H1 revenue rose just 5%. Q2 margin was boosted by milestone billings. FY27 growth guided only as 'in line' with last year.
Kfin reports consistent growth across all business lines despite challenging market macros.
Lumax reported strong 33% revenue growth, raising full-year guidance despite temporary margin pressure from West Asia conflict-related supply chain and raw material costs.